Replies to post #17112 on GeneSYS ID Inc fka GNID

[Penny Stocks 2.0]

Exactly, Moving forward as RXSF is still fundamentally sound. Great Patents, Great Innovative Product Line, Great Management Team & $80,000,000,000 in available Revenues. 1% puts RXSF @ $800,000,000 in Revenues and with more then 10 solid products and growing, those numbers are attainable down the road. You're dealing with consumer and professional healthcare plus governmental contracts.

Bring on the Investment Banker & Financing as well as the Buy Side Buyers.